中华肝脏病杂志
中華肝髒病雜誌
중화간장병잡지
CHINESE JOURNAL OF HEPATOLOGY
2014年
1期
30-32
,共3页
肝炎,乙型,慢性%肝硬化%生存质量
肝炎,乙型,慢性%肝硬化%生存質量
간염,을형,만성%간경화%생존질량
Hepatitis B,chronic%Liver cirrhosis%Quality of life
目的 探讨中药治疗慢性乙型肝炎肝纤维化的临床疗效并调查慢性乙型肝炎患者的生存质量. 方法 将430例慢性乙型肝炎肝纤维化患者随机分为治疗组和对照组.治疗组(220例)给予六味五灵片联合恩替卡韦分散片进行治疗,对照组(210例)仅给予恩替卡韦分散片,疗程均为12个月.比较两组患者治疗前后肝功能、肝纤维化情况、HBV DNA载量及肝脾影像学变化情况；同时,在治疗前后,应用WHOQOL-BRFE量表测量患者的生存质量.统计学分析采用t检验或x2检验. 结果 治疗后,两组患者的肝功复常率有明显改善(t值分别为7.51、8.12、7.88,P＜ 0.05)；血清肝纤维化指标较治疗前有明显改善(t值分别为7.01、6.55、6.10、8.01,P＜0.05)；门静脉内径及脾静脉内径较治疗前明显缩小,且两组间比较,差异有统计学意义(t值分别为4.099、2.231,P＜ 0.05)；两组患者HBV DNA转阴率较治疗前升高,但两组间差异无统计学意义；治疗后,两组患者的生存质量与治疗前相比,均有提升,并且除环境领域外,各领域差异均有统计学意义(P＜ 0.05).结论 中药治疗慢性乙型肝炎肝纤维化具有较好的疗效；同时,积极治疗能有效提高患者的生存质量.
目的 探討中藥治療慢性乙型肝炎肝纖維化的臨床療效併調查慢性乙型肝炎患者的生存質量. 方法 將430例慢性乙型肝炎肝纖維化患者隨機分為治療組和對照組.治療組(220例)給予六味五靈片聯閤恩替卡韋分散片進行治療,對照組(210例)僅給予恩替卡韋分散片,療程均為12箇月.比較兩組患者治療前後肝功能、肝纖維化情況、HBV DNA載量及肝脾影像學變化情況；同時,在治療前後,應用WHOQOL-BRFE量錶測量患者的生存質量.統計學分析採用t檢驗或x2檢驗. 結果 治療後,兩組患者的肝功複常率有明顯改善(t值分彆為7.51、8.12、7.88,P＜ 0.05)；血清肝纖維化指標較治療前有明顯改善(t值分彆為7.01、6.55、6.10、8.01,P＜0.05)；門靜脈內徑及脾靜脈內徑較治療前明顯縮小,且兩組間比較,差異有統計學意義(t值分彆為4.099、2.231,P＜ 0.05)；兩組患者HBV DNA轉陰率較治療前升高,但兩組間差異無統計學意義；治療後,兩組患者的生存質量與治療前相比,均有提升,併且除環境領域外,各領域差異均有統計學意義(P＜ 0.05).結論 中藥治療慢性乙型肝炎肝纖維化具有較好的療效；同時,積極治療能有效提高患者的生存質量.
목적 탐토중약치료만성을형간염간섬유화적림상료효병조사만성을형간염환자적생존질량. 방법 장430례만성을형간염간섬유화환자수궤분위치료조화대조조.치료조(220례)급여륙미오령편연합은체잡위분산편진행치료,대조조(210례)부급여은체잡위분산편,료정균위12개월.비교량조환자치료전후간공능、간섬유화정황、HBV DNA재량급간비영상학변화정황；동시,재치료전후,응용WHOQOL-BRFE량표측량환자적생존질량.통계학분석채용t검험혹x2검험. 결과 치료후,량조환자적간공복상솔유명현개선(t치분별위7.51、8.12、7.88,P＜ 0.05)；혈청간섬유화지표교치료전유명현개선(t치분별위7.01、6.55、6.10、8.01,P＜0.05)；문정맥내경급비정맥내경교치료전명현축소,차량조간비교,차이유통계학의의(t치분별위4.099、2.231,P＜ 0.05)；량조환자HBV DNA전음솔교치료전승고,단량조간차이무통계학의의；치료후,량조환자적생존질량여치료전상비,균유제승,병차제배경영역외,각영역차이균유통계학의의(P＜ 0.05).결론 중약치료만성을형간염간섬유화구유교호적료효；동시,적겁치료능유효제고환자적생존질량.
Objective To prospectively evaluate the efficacy of a traditional Chinese medicine (TCM)-based therapy for treating liver fibrosis in patients with chronic hepatitis B (CHB),and to investigate the patients' perception of the treatment's effects on quality of life (QoL).Methods A total of 430 patients with CHB-related liver fibrosis were randomly assigned to treatment groups for receipt of a 12-month course of the antiviral drug entecavir alone (control group) or in combination with the TCM Liuweiwuling tablets.Patients were assessed before (pre-treatment) and after therapy and the treatment-related differences in clinical manifestations,levels of liver function markers and liver fibrosis indexes,color ultrasound images,and hepatitis B virus (HBV) DNA load were compared between the two groups by statistical analysis.The generic QoL scale developed by the World Health Organization (WHOQOL-BREF) was used to score the patients' perceptions of treatment outcome.Results After treatment,the patients in both groups showed significant improvement in the majority of clinical manifestations (both P ＜ 0.05),with the exception of bloating.In addition,both groups showed significant improvements of liver function markers and in signs of liver fibrosis (both P ＜ 0.05).Both groups also showed significant reductions in the diameters of the portal and splenic (both P ＜ 0.05),as well as increases in the rate of undetectable HBV DNA (with a statistically similar outcome achieved in the two groups).Finally,both groups had higher QoL scores after treatment,with all assessed parameters except environment showing a significant improvement (all P ＜ 0.05).Conclusion When used in combination with entecavir,the TCM Liuweiwuling tablet is a safe therapy for CHB and its related liver fibrosis and may help to improve the QoL of these patients.
